From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. HIV/AIDS Clinical Care>
  4. Drug Watch

HIV/AIDS Clinical Care: Drug Watch

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.


to
Items 1-10 of 19 are shown

Etravirine Can Cause Severe Skin and Hypersensitivity Reactions

Severe skin or hypersensitivity reactions should prompt immediate cessation of the drug.

Label Change for Lopinavir/Ritonavir

The revision reflects the drug’s potential for prolonging both the PR interval and the QT interval.

Darunavir Now Approved for Use in Treatment-Naive Patients

Approval is based on a 48-week comparison of ritonavir-boosted darunavir with lopinavir/ritonavir.

Update on Nelfinavir

Nelfinavir can once again be prescribed to children and pregnant women.

  • May 19, 2008

Cefixime Tablets Available in the U.S. Again

Cefixime tablets (Suprax; 400 mg) are now available in the U.S. for the first time since 2002. Cefixime is the only CDC-recommended oral treatment for . . .

  • By ACC Editors
  • May 5, 2008
  • Covering:
    • Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2008 Apr 25; 57:435

Abacavir or ddI Therapy and MI Risk?

The FDA has issued an early communication citing the potential association between use of abacavir or ddI and increased risk for myocardial infarction (MI). The . . .

  • April 7, 2008
  • Covering:
    • U.S. Food and Drug Administration., 2008 Mar 27

Label Change for Darunavir

The revision reflects the drug’s potential for hepatotoxicity.

Darunavir Now Available in 600-mg Tablets

The FDA has approved a new strength of darunavir that will reduce pill burden: The drug is now available in 600-mg tablets, as well as . . .

  • March 3, 2008
  • Covering:
    • FDA., 2008 Feb 25

Revised Package Insert for Atazanavir

The insert includes new information on administering the drug with acid-reducing therapies and on appropriate dosing in patients with renal failure.

FDA Approval: Etravirine

Etravirine is highly effective against most viruses with resistance to other NNRTIs. Clinicians will need to be especially aware of the determinants of cross-resistance and of some significant drug–drug interactions.

Items 1-10 of 19 are shown

to

Search

Advanced

Sign-In

Forgot your password?

New to Journal Watch?





Copyright © 2009. Massachusetts Medical Society. All rights reserved.